11 March 2021
The Coalition for Epidemic Preparedness Innovations (CEPI) and biopharmaceutical company VBI Vaccines have entered into a partnership to advance and develop the latter’s enveloped virus like particle (eVLP) vaccine candidates against Covid-19 variants. CEPI will offer up to $33m to support the development of VBI-2905, a monovalent eVLP candidate, in a Phase I clinical trial.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Softbox announced that it will be supporting Pfizer in the global distribution of Covid-19 vaccines. The vaccines will be transported in a high-performance temperature controlled parcel shipper developed precisely for ultra-low temperature products.
Moderna announced that it has successfully dosed the first participants with its modified Covid-19 vaccines in an amended ongoing Phase II clinical study. mRNA-1273.351 is being evaluated as a booster vaccine to assess a broader immune response to emerging variants, while mRNA-1273.211 is a multivalent candidate which combines mRNA-1273, Moderna’s authorised vaccine against ancestral strains.
